Key points are not available for this paper at this time.
LAM-cell/fibroblast interactions attract mast cells where tryptase release contributes to disease progression. Repurposing SCG for use in LAM should be studied as an alternative or adjunct to mTOR inhibitor therapy.
Babaei‐Jadidi et al. (Wed,) studied this question.